A Pryce, Eerden E Van, M Cody, J Oakes, A DeSalvo, S Bannon, C Burlton, R Pawson, W Fingrut, F Barriga, J Ward, C Ingram, M Walsh, K El-Ghariani, S Ocheni, L Machin, D Allan, T Mengling, C Anthias
Following hematopoietic cell transplantation, recipients are subjected to extensive genetic testing to monitor the efficacy of the transplant and identify relapsing malignant disease. This testing increasingly includes the use of large gene panels which may lead to incidental identification of genetic and molecular information of potential donor origin. Deciphering whether variants are of donor origin, and if so, whether there are clinical implications for the donor, can prove challenging. In response to queries from donor registries and transplant centers regarding best practice in managing donors when genetic mutations of potential donor origin are identified, the Medical Working Group of the World Marrow Donor Association established an expert group to review available evidence and to develop a framework to aid decision-making...
December 4, 2023: Transplantation and cellular therapy